Title: Complications in Indian Pharmaceutical Industry with Special Reference to Intellectual Property Rights
Abstract: The IPR is well known as concepts, innovations, and innovative jargons that are founded on the public inclination to seek property status. In order to allow IPR to derive commercial profits from their artistic effort or prestige, they grant elite rights to the inventors or creators of that property. There are several forms of protection against intellectual property such as patent, copyright, trademark, etc. Patent is the approval of an innovation that meets the worldwide creativity, non-obviousness and commercial use standards. In order to help identify, prepare, market, make and, thus, secure the innovation or imagination, IPR is a necessary prerequisite. Any industry should make progress by developing its own advanced IPR policies, management style, techniques, etc., based on its field of expertise. Currently, the pharmaceutical industry has established an IPR policy that requires better attention in the next century. This research focuses mainly on both the challenges of the companies and the opportunities that Indian Pharmaceutical companies have in the form of IPR. The common problems with IPR with particular regard to Indian Pharmaceutical companies have given this study greater opportunities. As Indian pharmaceutical firms are justly starting to invest in R&D and to produce their own patented molecules, it is irrefutable that they want to shield their innovation with patents. The Indian government should also promote and protect foreign corporations' patents. For the industry, and for research and development, patent protection and other types of intellectual property (IP) rights are essential. Without strong fortification companies have no incentives for research and development or the development of new, advanced medicines, particularly pharmaceutical companies.
Publication Year: 2019
Publication Date: 2019-02-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot